Bharat Tewarie - UCB SA Insider

UCBJY -- USA Stock  

USD 40.23  1.83  4.77%

Dr. Bharat Tewarie has served as Executive Vice President, Chief Marketing Officer, Member of the Executive Committee of UCB S.A. since March 2015. He joined the Company in March 2015. He received an MBA from Webster University in 1991, and a Masters degree from Universiteit Utrecht in 1986. He joined UCB with 27 years of experience in the biotech industry. He has acquired worldwide expertise while leading global business unit teams to great success. His past experience in domains such as immunology and neurology are a great match to UCBs core focus areas. His knowledge of markets around the world is also key to helping UCB prepare for future product launches. Trained as a medical doctor, he also has background in multiple aspects of pharmaceutical management, including PL responsibility, business development, sales, global marketing, clinical research and medical affairs. At UCB he heads the Global Strategic Marketing Practice and is a member of the Executive Committee. Key positions Prior to UCB 2012 2014 EMD Serono Inc. Senior Vice President, Head of the Global Business Franchise Neurology and Immunology and of the Global Business Franchise Medical Devices 2010 2011 Merck Serono SA Senior Vice President, Head of Global Business Unit Fertility Endocrinology 1998 2010 During this timeframe, Bharat held various leadership positions at Serono International SA, Serono Inc and EMD Serono in Endocrinology and Reproductive Health covering areas such as global sales and marketing, US business unit management and business development Prior to this, he built up his global and local experience with other companies Roche Pharma and Boehringer Ingelheim.
Age: 56  President Since 2015  MBA    
32 2 559 99 99

Management Efficiency

The company has return on total asset (ROA) of 6.67 % which means that it generated profit of $6.67 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 13.73 % meaning that it generated $13.73 on every $100 dollars invested by stockholders.
The company has accumulated 1.83 B in total debt with debt to equity ratio (D/E) of 27.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. UCB SA has Current Ratio of 1.34 which is within standard range for the sector.

Similar Executives

Entity Summary

UCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system. UCB SA was founded in 1928 and is based in Brussels, Belgium. UCB SA operates under Biotechnology classification in USA and traded on OTC Market. It employs 7478 people.UCB SA (UCBJY) is traded on OTC Market in USA. It is located in All?e de la Recherche, 60 and employs 7,478 people.

UCB SA Leadership Team

Pascale Richetta, Executive Vice President Bone Patient Value Unit Head, Member of the Executive Committee
Detlef Thielgen, CFO and Executive VP
Kay Davies, Independent Director
Dirk Teuwen, VP Corporate Societal Responsibility
Anna Richo, Executive VP and General Counsel
Viviane Monges, Independent Non-Executive Director
Gerhard Mayr, Non-Executive Chairman of the Board
Cyril Janssen, Director
Cedric Rijckevorsel, Director
JeanChristophe Tellier, Chairman of the Executive Committee, CEO
Arnoud Calesberg, Non-Executive Director
Mark McDade, COO and Executive VP
Xavier Michel, Vice President and Secretary General
Dhavalkumar Patel, Executive Vice President Chief Scientific Officer, Member of the Executive Committee
Bharat Tewarie, Executive Vice President Chief Marketing Officer
Roch Doliveux, Chairman of the Executive Committee, CEO, Executive Director
Norman Ornstein, Non-Executive Independent Director
Jeff Wren, Executive Vice President Neurology ? Patient Value Unit Head
JeanPierre Kinet, Non-Executive Independent Director
Antje Witte, VP of Investor Relations
Alice Dautry, Independent Director
Harriet Edelman, Non-Executive Independent Director
Ulf Wiinberg, Independent Director
Thomas McKillop, Non-Executive Independent Director
Charl Zyl, Executive Vice President Head of Patient Value Operations, Member of the Executive Committee
France Nivelle, VP Global Communication
Fabrice Enderlin, Executive Vice President - Human Resources & Communication, Member of the Executive Committee
Pierre Gurdjian, Independent Director
Ismail Kola, Chief Scientific Officer, Head of New Medicines Patient Value Unit and Executive VP
Emmanuel Caeymaex, Executive Vice President Immunology - Patient Value Unit Head
Evelyn Bergendal, Non-Executive Vice Chairwoman of the Board
Iris LoewFriedrich, Executive Vice President Chief Medical Officer
CharlesAntoine Janssen, Non-Executive Director
Albrecht Graeve, Non-Executive Independent Director
JeanLuc Fleurial, Executive Vice President Chief Talent Officer, Member of the Executive Committee
Alexander Moscho, Executive Vice President Chief Strategy Officer, Member of the Executive Committee

Stock Performance Indicators

Current Sentiment - UCBJY

UCB SA Investor Sentiment
Macroaxis portfolio users are unemotional in their outlook on investing in UCB SA. What is your outlook on investing in UCB SA? Are you bullish or bearish?
50% Bullish
50% Bearish

Also Currentnly Active

Purchased over 20 shares of
a day ago
Traded for 106.27
Purchased over 200 shares of
a day ago
Traded for 10.56
Purchased over 70 shares of
a day ago
Traded for 39.4
Also please take a look at World Market Map. Please also try Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.